thermo离子阱药物杂质分析

《thermo离子阱药物杂质分析》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、多级质谱技术深入剖析化合物结构离子阱多级液质药物杂质分析解决方案目录序言··························································································································································3杂质分析工作流程····································································································

2、···························4离子阱质谱技术介绍··························································································································5离子阱质谱原理··································································································································5T

3、hermo专利的线性离子阱质谱··········································································································6数据采集·················································································································································7多种扫描方式·····················

4、·················································································································7目标杂质分析······································································································································7未知杂质分析······································

5、································································································8数据分析·················································································································································9MassFrontier专业结构解析软件································

6、·········································································9离子阱质谱在药物杂质分析中的应用························································································11线性离子阱多种解离技术对阿德福韦酯杂质谱的全面鉴定·······························································11应用LCQ离子阱质谱仪和MassFrontier软件分析药

7、物中间体的痕量杂质成分·······························15药物杂质分析部分客户文章列表·································································································18附录···············································